Mgi Pharma Inc

Mgi Pharma — Needham Biotechnology Conference 2004

22 slides from Mgi Pharma's conference presentation, Jun 16, 2004

  1. Slide 1: MGI PHARMA, INC. Poised for Success

    MGI PHARMA, INC. Poised for Success Presented June 16, 2004 Needham Biotechnology Conference

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements This presentation contains forward-looking statements that involve risks and uncertainties, including those described in the Company’s Securities and Exchange Commission filings.

  3. Slide 3: Mission

    MGI PHARMA Mission MGI PHARMA is an oncology-focused biopharmaceutical company We acquire, develop and commercialize proprietary pharmaceutical products that address the needs of cancer patients

  4. Slide 4: 2003 Business Highlights

    MGI PHARMA 2003 Business Highlights Marketed products – AloxiTM (palonosetron HCl) injection approved by the FDA on July 25 and launched September 15 Business development – Expanded Aloxi rights to include postoperative nausea & vomiting and an oral formulation Product development – Advanced irofulv

  5. Slide 5: Business Development & Licensing Focus

    MGI PHARMA Business Development & Licensing Focus Supportive Care – Nausea & vomiting – Myelosuppression – Mucositis & xerostomia – Pain – Infection – Other organ toxicities Therapeutic Approaches – Cytotoxics – Targeted small molecules – Monoclonal antibodies – Protein therapeutics

  6. Slide 6: A Balanced Portfolio Of Oncology Products

    Product Portfolio A Balanced Portfolio Of Oncology Products Preclinical Phase 1 Phase 2 Phase 3 Approved Market AloxiTM Injection (CINV) Salagen® Tablets Hexalen® Capsules AloxiTM Injection (PONV) AloxiTM oral formulation Irofulven Monotherapy Combination Therapy Other Acylfulvene Analogs MG98

  7. Slide 7: Aloxi Injection: The Best-In-Class 5-HT3 Antagonist For CINV

    AloxiTM Injection The Best-In-Class 5-HT3 Antagonist For CINV Approved for both acute and delayed chemotherapy-induced nausea & vomiting (CINV) Favorable head-to-head trials compared to market leaders – Strong binding affinity (potency) – Long half life – Extended activity Exclusive U.S. & Canadian

  8. Slide 8: U.S. 5-HT3 Cancer Market Approaching $1 B

    AloxiTM Injection U.S. 5-HT3 Cancer Market Approaching $1 B $1,800,000 $1,600,000 $1,400,000 $1,200,000 $1,000,000 $800,000 $600,000 $400,000 $200,000 $0 Cancer market PONV/other Includes all indications, both I.V. and oral formulations. Ref: IMS National Sales Perspective report.

  9. Slide 9: Cancer Market Segments

    AloxiTM Injection Cancer Market Segments Chemotherapy is most often administered in oncology offices – Oncology GPOs and specialty distributors are important Hospital outpatient cancer centers are the second largest segment Hospital inpatient accounts for ~ 10% of the market Source of Market $ 35% 1

  10. Slide 10: A Differentiated 5-HT3 Receptor Antagonist

    AloxiTM Injection A Differentiated 5-HT3 Receptor Antagonist 5-HT3 product Company Launch [-log(Ki)]* Half-life AloxiTM MGI Sept. 2003 10.45 40 hours Zofran® GSK Feb. 1991 8.39 4 hours Kytril® Roche Mar. 1994 8.91 9 hours Anzemet® Aventis Nov. 1997 7.60 7.5 hours * In-vitro receptor binding studies

  11. Slide 11: Phase III Results Demonstrate Greater Efficacy For Acute And Delayed Emesis

    AloxiTM Injection Phase III Results Demonstrate Greater Efficacy For Both Acute And Delayed Emesis Prevention* Complete Response Rates (no emesis or rescue meds) Acute (0-24 hrs) vs. comparator* Delayed (24-120 hrs) vs. comparator* Study 99-03 Study 99-04 99-05 Subset AloxiTM Zofran® AloxiTM Zofran®

  12. Slide 12: Positioned For Success

    AloxiTM Injection Positioned For Success Team of 100+ field-based professionals targeting: – ~2,400 oncology clinics – ~800 hospitals Concentrated focus on ~10,000: – MedOncs, HemOncs, RadOncs and GynOncs Strategy to differentiate – Pharmacology – Efficacy – Convenience – Reimbursement Sales Call Ap

  13. Slide 13: Aloxi Launch Success

    AloxiTM Launch Success Weekly End-user Demand

  14. Slide 14: Clinical Candidates Portfolio

    Product Portfolio Clinical Candidates Preclinical Phase 1 Phase 2 Phase 3 Approved Market AloxiTM Injection (CINV) Salagen® Tablets Hexalen® Capsules AloxiTM Injection (PONV) AloxiTM oral formulation Irofulven Monotherapy Combination Therapy Other Acylfulvene Analogs MG98

  15. Slide 15: Irofulven: A Novel, Broadly Active Cytotoxic

    Irofulven A Novel, Broadly Active Cytotoxic New chemotherapeutic class Novel mechanism of action – Binds to DNA & protein targets – DNA strand breakage, inhibition of DNA synthesis & repair – Tumor-specific apoptotic cell death – Activity independent of P53 and bcl-2 status Monotherapy activity in p

  16. Slide 16: Irofulven Clinical Program Overview

    Irofulven Clinical Program Overview Irofulven Preclinical Phase 1 Phase 2 Phase 3 Liver Gastric* Combination with Camptosar®** Combination with Gemzar® Combination with Taxotere® Combination with cisplatin Combination with Xeloda® Combination with oxaliplatin *National Cancer Institute trial ** Colo

  17. Slide 17: Demonstrated Combination Activity in HRPC

    Irofulven Demonstrated Combination Activity in HRPC Irofulven + Capecitabine: PSA CR in HRPC Patient Irofulven + Cisplatin: PSA CR in HRPC Patient End of Treatment

  18. Slide 18: Hormone Refractory Prostate Cancer Program

    Irofulven Hormone Refractory Prostate Cancer Program • Phase 2 multicenter combination program designed to evaluate irofulven + prednisone in combination – Capecitabine – Platinum agent • Patients previously treated with taxanes • Endpoints include: – Pain palliation – Clinical benefit – Time to dis

  19. Slide 19: FY 2004 Financial Guidance

    FY 2004 Financial Guidance Provided April 14, 2004 - Aloxi injection sales of $115 to $130 million - Other product sales of approx. $27 million - Licensing revenue of approximately $2 million - Cost of product sales as a percent of sales revenue of approximately 30% - SG&A expenses of approximately

  20. Slide 20: Balance Sheet

    Balance Sheet (in thousands) March 31, 2004 Actual Cash and Marketable Investments $ 400,737 Total Assets $ 468,660 Long-term Debt $ 260,172 Total Shareholders’ Equity $ 183,870 Shares Outstanding 35,143

  21. Slide 21: Focused Execution

    MGI PHARMA Focused Execution Successfully launch Aloxi injection and rapidly penetrate the $1 billion CINV market Leverage sales force by launching in-licensed, acquired and co-promoted products Advance the development of clinical product candidates, including Aloxi injection for PONV, oral formulat

  22. Slide 22: MGI PHARMA, INC. Poised for Success

    MGI PHARMA, INC. Poised for Success NASDAQ: MOGN www.mgipharma.com

MGI Pharma — Needham Biotechnology Conference 2004 on 6ix